Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Net Income: 2009-2025

Historic Net Income for Aytu Biopharma (AYTU) over the last 17 years, with Sep 2025 value amounting to $2.0 million.

  • Aytu Biopharma's Net Income rose 415.75% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year increase of 195.99%. This contributed to the annual value of $620,000 for FY2025, which is 118.65% up from last year.
  • Aytu Biopharma's Net Income amounted to $2.0 million in Q3 2025, which was up 3,069.35% from $62,000 recorded in Q2 2025.
  • Aytu Biopharma's Net Income's 5-year high stood at $2.0 million during Q3 2025, with a 5-year trough of -$53.3 million in Q1 2022.
  • In the last 3 years, Aytu Biopharma's Net Income had a median value of -$599,000 in 2024 and averaged -$956,545.
  • Its Net Income has fluctuated over the past 5 years, first plummeted by 546.80% in 2021, then surged by 415.75% in 2025.
  • MRQ analysis of 5 years shows Aytu Biopharma's Net Income stood at -$11.5 million in 2021, then surged by 42.04% to -$6.7 million in 2022, then soared by 87.46% to -$839,000 in 2023, then surged by 114.66% to $123,000 in 2024, then soared by 1,497.56% to $2.0 million in 2025.
  • Its Net Income stands at $2.0 million for Q3 2025, versus $62,000 for Q2 2025 and $54,000 for Q1 2025.